Firms to investigate RNAi for Huntington's disease

12/27/2010 | Wall Street Journal, The

Alnylam Pharmaceuticals and Medtronic have teamed up to develop a treatment for Huntington's disease using RNA interference, which can focus on a gene responsible for the production of disease-causing proteins. Medtronic will develop a catheter or a pump that can deliver Alnylam's short, interfering RNA drug directly to the correct area of the brain.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ